TIBEAY Biosciences is a clinical-stage biotechnology company based in the Netherlands focused on developing innovative therapies for acute neurological diseases. Its lead candidate, Ronopterin, is described as a first-in-class inhibitor of inducible nitric oxide synthase (iNOS) intended to reduce secondary brain damage after severe traumatic brain injury (SHT). The company plans a European multicenter Phase 3b study and aims to submit a marketing authorization application to the EMA based on that trial. The recently completed €35 million financing will fund the Phase 3b study, production of the investigational product, supply-chain activities, and regulatory and operational preparations for potential approval. TIBEAY is engaging investors including Münchner Athos KG, MIG Fonds, Meneldor and Oost NL to support its clinical and regulatory programs. The company positions Ronopterin as targeting an unmet medical need where no approved pharmacologic therapies currently exist.

Total raised

$41M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2026